Allogene Therapeutics Inc
NASDAQ:ALLO

Watchlist Manager
Allogene Therapeutics Inc Logo
Allogene Therapeutics Inc
NASDAQ:ALLO
Watchlist
Price: 2.54 USD -6.62% Market Closed
Market Cap: 531.1m USD
Have any thoughts about
Allogene Therapeutics Inc?
Write Note

Allogene Therapeutics Inc
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Allogene Therapeutics Inc
Interest Income Expense Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Allogene Therapeutics Inc
NASDAQ:ALLO
Interest Income Expense
$34.3m
CAGR 3-Years
123%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Interest Income Expense
-$2B
CAGR 3-Years
7%
CAGR 5-Years
-9%
CAGR 10-Years
-13%
Gilead Sciences Inc
NASDAQ:GILD
Interest Income Expense
-$948m
CAGR 3-Years
26%
CAGR 5-Years
-6%
CAGR 10-Years
-10%
Amgen Inc
NASDAQ:AMGN
Interest Income Expense
-$2.4B
CAGR 3-Years
-34%
CAGR 5-Years
-29%
CAGR 10-Years
-15%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Interest Income Expense
$595.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Interest Income Expense
$990m
CAGR 3-Years
23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Allogene Therapeutics Inc's Interest Income Expense?
Interest Income Expense
34.3m USD

Based on the financial report for Sep 30, 2024, Allogene Therapeutics Inc's Interest Income Expense amounts to 34.3m USD.

What is Allogene Therapeutics Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
14%

Over the last year, the Interest Income Expense growth was 132%. The average annual Interest Income Expense growth rates for Allogene Therapeutics Inc have been 123% over the past three years , 14% over the past five years .

Back to Top